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1, 2005 through December 31, 2011 for patients with commercial or employer-
sponsored supplemental Medicare insurance. Bevacizumab claims were 
excluded if the claim had a diagnosis related to macular degeneration or other 
eye disease. Claims for both drugs were excluded from the payment analysis if 
the reimbursed amount was less than $100. All claims were identified as 
occurring in an office-based setting (OBS), an outpatient hospital setting (OHS) or 
other setting. RESULTS: The percent of bevacizumab claims occurring in OHS 
increased from 6 to 37% among Medicare claims, and from 15 to 42% among 
commercial claims from 2005 to 2011. For trastuzumab, the increases were 9 to 
33%, and 17 to 37% in Medicare and commercial claims, respectively. Median 
bevacizumab reimbursement increased 56% ($3000 to $4681) for OBS and 125% 
($3438 to $7739) for OHS from 2005 to 2011 in commercial claims. For Medicare 
claims, the increases were 88% ($2284 to $4284) and 111% (2284 to $4827) for OBS 
and OHS, respectively. For trastuzumab commercial claims, median 
reimbursement increased 47% ($2037 to $2996) and 88% ($2749 to $5171) for OBS 
and OHS; while for Medicare the increases were 68% ($1697 to $2854) and 67% 
($1704 to $2838), respectively. CONCLUSIONS: The shift in chemotherapy 
administration from OBS to OHS and related growth in reimbursement for 
outpatient hospital settings relative to office settings has implications for the 
growth in cancer costs over the past decade. Further research is warranted to 
understand the drivers of the shift in location and whether future policies should 
address reversing the shift.  
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OBJECTIVES: To analyze the cost of care in oncology inpatients in Brazilian 
private hospitals and their spending on medicine (chemotherapy and palliative 
care). METHODS: We selected patients who consume antineoplastic medicines 
in Orizon database (16 million lifes) within a 12-month period and analyzed their 
medical bills, appointments and hospitalizations (direct costs) and also 
medicines for palliative treatment. RESULTS: We identified 1244 patients who 
consume an annual average of R$ 6,342.51 in outpatient use of anticancer drugs 
per patient and their medical bills US$30,320.78 in expenses with a mean 
hospital stay of 4.60 days with 4, 48 consultations per patient to the cost of 
R$210.56 and the cost of medicines for palliation of R$6,277.16 (regulators of bone 
metabolism, corticosteroids, antidepressants, anti-inflammatories, diuretics, 
antiemetics, anticonvulsants, analgesics, vitamins and antispasmodics) 
CONCLUSIONS: The direct costs of cancer patients is not restricted only hospital 
infusions and their admissions, but also outpatient expenditures such as oral 
medications and palliative treatments.  
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OBJECTIVES: The prognosis of melanoma patients with brain metastases is poor, 
with median overall survival of approximately 4-5 months. This is the first study 
aiming at quantifying medical resources utilization and direct health care costs 
associated with brain metastases among metastatic melanoma patients in the 
U.S. METHODS: A retrospective pre-post design was implemented using data 
from the Truven MarketScan claims database (2000Q1-2011Q3). Patients with ≥1 
diagnosis of melanoma (ICD-9-CM: 172-173, 198.2), ≥1 diagnosis of brain 
metastases (ICD-9-CM: 198.3), and ≥18 years as of the first observed brain 
metastases diagnosis (index date) were identified. The pre-period was defined as 
the 6 months prior to the index date and post-period as the period following the 
index date up to the earliest of 12 months, recorded death, or loss to follow up. 
All-cause and brain metastasis-related medical resources and health care costs 
were compared on a per patient per month (PPPM) basis between the pre- and 
post-periods. RESULTS: The study population consisted of 6076 patients; mean 
(SD) age was 63.4 (13.4) years and 57.6% males. Significant differences were 
observed between the post- and pre-period in mean all-cause PPPM 
hospitalizations (0.21 vs. 0.08), emergency department visits (0.12 vs. 0.08), and 
outpatient visits (4.48 vs. 3.74) (p<.0001 for all). Similar results were found for 
brain metastasis-related hospitalizations (0.15 vs. 0.04), emergency department 
visits (0.02 vs. 0.01), and outpatient visits (2.00 vs. 1.17) (p<.0001 for all). 
Significant post- vs. pre-period differences were also observed in the PPPM all-
cause health care costs (total: $14,489 vs. $7,277; inpatient: $6,330 vs. $1,900; 
outpatient: $6,609 vs. $4,449; p<.0001 for all) and brain metastasis-related costs 
(total: $6,542 vs. $1,933; inpatient: $2,976 vs. $472; outpatient: $3,451 vs. $1,413; 
p<.0001 for all). CONCLUSIONS: The economic burden associated with brain 
metastases in melanoma is significant and underscores the need for newer 
therapies improving outcomes among these patients.  
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OBJECTIVES: Prolonged air leaks (PAL) lasting >5 days occur in up to 50% of all 
patients undergoing lung volume reduction surgery (LVRS); resulting in increased 
length of stay (LOS), patient morbidities, and health care costs. We sought to 
map care path options for the management of PAL following LVRS among 
emphysematous patients, and to report estimates of associated costs. 
METHODS: Peer-reviewed English language articles from January 2000 – 
September 2012 were searched using pre-identified terms. A typical care path for 
a male smoker with emphysema was mapped from diagnosis to removal of chest 
tube after LVRS. Parameters extracted from the identified articles were 
country/region, year, type of study, type of procedure [open vs. video-assisted 
thoracoscopic surgery (VATS)], number of patients, cost, LOS and complication 
rates. RESULTS: The care path captured treatment events from diagnosis of 
nodules to post-surgical follow up care. PAL treatment options included the 
Heimlich valve, autologous blood patch or both prior to discharge. Eleven studies 
reporting cost data for 4,945 VATS procedures and 18,033 open procedures were 
identified. LOS [3.0 – 17.3 days (VATS) versus 5.0 to 23.8 days (open)], hospital 
costs [US unadjusted: $10,084 to $23,826 (VATS) versus $12,119 - $25,125 (open)] 
and complication rates were lower for VATS versus open procedures. Similar 
cost differences were reported in Korea, Japan and China. Post-discharge care 
and cost of patients with PAL were driven by the utilization of home health care, 
increased pain management costs, more frequent doctor visits and delayed 
return to work. CONCLUSIONS: There is wide variability in the care path options 
associated with management of PAL and associated complications during LVRS 
in emphysema patients. VATS appears to have a positive health care utilization 
and cost advantage versus open procedures globally. Further analyses are 
needed to quantify the true cost of care associated with managing PAL in LVRS 
patients.  
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OBJECTIVES: To evaluate the cost-effectiveness of cabazitaxel in 2L metastatic 
castration resistant prostate cancer (mCRPC) patients who progressed after 
docetaxel (D) from the Swedish health care perspective in a subgroup of the 
TROPIC trial (NCT00417079) METHODS: A Markov cohort based cost effectiveness 
model was used. Transition rates between the health states representing mCRPC 
disease progression (stable, progression, death) were estimated based on 
progression of disease and survival rates from the TROPIC trial. The efficacy and 
safety data is based on the results of the TROPIC trial, which compares 
cabazitaxel plus prednisone to mitoxantrone plus prednisone in patients 
previously treated with docetaxel. Resource inputs were obtained from 
literature, hospital data and key opinion leaders. The subgroup is defined as 
those patients who initially responded to D but experienced disease progression 
<3 months since last D dose. At the time of the trial, the combination of 
Mitoxantrone (M) and Prednisone (P) was considered to be an appropriate second 
line comparator. Hence, in the base-case, M + P is the main comparator, in 
accordance with the TROPIC trial design. In addition, an indirect comparison 
versus P alone was carried out. Costs in added life years were added in the model 
to follow the societal perspective of Swedish health care system. RESULTS: In 
the base case analysis, total costs were estimated to be 699 176 SEK for 
Cabazitaxel, 320 491 SEK for M+P and 302 726 SEK for P alone. For the TROPIC 
subgroup, the ICER for C+P vs M+P was 943 270 SEK/QALY, ICER for C+P vs P 
alone was 990 903 SEK/QALY . Based on historical decision making by TLV, the 
threshold in Sweden is 1,000,000 SEK/QALY. CONCLUSIONS: Cabazitaxel appears 
to be a cost effective option compared with mitoxantrone and prednisone in the 
subgroup of TROPIC in Swedish health care setting.  
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OBJECTIVES: To evaluate the cost-effectiveness of posaconazole versus 
fluconazole/ itraconazole in invasive fungal infection (IFI) prevention among 
patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes 
(MDS) and at high risk of IFI due to chemotherapy-induced neutropenia in 
Singapore. METHODS: A decision-analytic model previously developed for the US 
and other countries was adapted to Singapore, to estimate the cost-effectiveness 
of antifungal prophylaxis with posaconazole compared to fluconazole/ 
itraconazole among AML or MDS patients at high risk of IFI. Patients were 
assumed to receive prophylaxis with posaconazole or fluconazole/ itraconazole. 
Probabilities of IFI, IFI-related death, and other cause death within 100 days of 
follow-up were estimated from clinical trial data. Trial results were extended to a 
lifetime horizon by modeling cancer-specific mortality, estimated from 
published sources, in one-month Markov cycles. Prophylaxis and IFI treatment 
costs were estimated using data obtained from two hospitals in Singapore. Model 
